PTNPALATIN TECHNOLOGIES, INC.
Is Palatin Technologies struggling financially?
Yes, by its own account. Palatin Technologies told the SEC on 14 Nov 2025, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Nov 2025
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $17.2M
- Source filing
- 10-Q 14 Nov 2025
- Balance sheet
- 31 Mar 2026
Cash runway
-
4months
If the burn speeds up
Empty by Jul 2026
-
7months
If it eases off
Empty by Oct 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$10.2M
÷
Cash burned over the last 12 months
$21.3M
What Palatin Technologies told the SEC
…$ 16,900,000 in net proceeds from a public offering which closed on November 12, 2025, management has concluded that the prior conditions and events raising substantial doubt about the Company’s ability to continue as a going concern no longer exist as of the date these financial statements are issued. Based on the company's operating and development plan, The Company expects that its existing cash and cash…
PALATIN TECHNOLOGIES, INC., Form 10-Q, filed 14 Nov 2025.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 453.8% share-count increase The company issued stock. Each share now owns 81.9% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 50% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- ADVB Advanced Biomed $13.4M
- AIM Aim Immunotech $7.9M
- BGLC BioNexus Gene Lab $4.7M
- VSTM Verastem $624.0M
- CRVO CervoMed $39.6M
- IMNN Imunon $9.2M